{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-275888","form_type":"8-K","ticker":"CALC","cik":"0001534133","company_name":"CalciMedica, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.670772+00:00","generated_at":"2026-05-16T21:08:51.686338+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CalciMedica Q3 net loss $7.8M ($0.52/shr); cash $14.1M, funds into 2H 2026","bullets":["Net loss of $7.8M ($0.52 per share), up from $5.6M ($0.50) a year ago.","Cash, equivalents, and short-term investments at $14.1M; expected to fund operations into 2H 2026.","Phase 2 KOURAGE trial in AKI with respiratory failure enrollment ongoing; data expected 1H 2026.","Positive FDA discussions on acute pancreatitis pivotal trial; final design expected 1H 2026.","Collaboration with Telperian to leverage AI analytics for pivotal trial design."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-275888","json":"https://secwatch.observer/filing/0001193125-25-275888.json","markdown":"https://secwatch.observer/filing/0001193125-25-275888.md","text":"https://secwatch.observer/filing/0001193125-25-275888.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534133/000119312525275888/0001193125-25-275888-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534133/000119312525275888/ck0001534133-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:08:51.686338+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}